Fluphenazine Enanthate

CHEMBL1200951 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

549.7 g/mol

LogP

7.4

Phase

4

This medium-acting injectable ester form of fluphenazine provides sustained release of the antipsychotic medication over approximately one to two weeks. It is used in patients with schizophrenia who require regular antipsychotic coverage without daily oral dosing.

Molecular Weight

549.7000 g/mol

LogP

7.40

TPSA

61.30 Å²

Lipinski RO5

Fail

Mechanism of Action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

InChI

InChI=1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3

Molecular Formula

C29H38F3N3O2S

HBD / HBA

- / 9

Rotatable Bonds

13

Heavy Atoms

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This medium-acting injectable ester form of fluphenazine provides sustained release of the antipsychotic medication over approximately one to two weeks. It is used in patients with schizophrenia who require regular antipsychotic coverage without daily oral dosing.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Fluphenazine Enanthate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200951. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3389. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Fluphenazine Enanthate on PillFYI

Structure

Quick Data

Formula: C29H38F3N3O2S

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.